Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.55 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP2A13 | Q16696 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | DBH | P09172 | 1/20 | 0.38 |
| ▸ | PTPRC | P08575 | 1/20 | 0.37 |
| ▸ | PTPRG | P23470 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL96464 | 0.82 | TAAR1 (0.52) | PNMTTAAR1IDO1CYP1A2CYP3A4 | |
| SCHEMBL16952334 | 0.79 | GABRA1 (0.38) | PNMTTAAR1ALDH1A1CYP2D6 | |
| SCHEMBL7438258 | 0.79 | TAAR1 (0.57) | PNMTTAAR1IDO1KDM4EALDH1A1 | |
| SCHEMBL16958334 | 0.79 | ALDH1A1 (0.42) | PNMTTAAR1ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL29763190 | 0.78 | PNMT (0.56) | PNMTTAAR1IDO1KDM4EALDH1A1 | |
| SCHEMBL310847 | 0.78 | PNMT (0.56) | PNMTTAAR1IDO1KDM4EALDH1A1 | |
| SCHEMBL16957570 | 0.76 | XDH (0.41) | PNMTTAAR1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1683184 | 0.75 | IDO1 (0.60) | PNMTTAAR1IDO1KDM4EALDH1A1 | |
| SCHEMBL11195030 | 0.75 | ALDH1A1 (0.41) | PNMTTAAR1IDO1KDM4EALDH1A1 | |
| SCHEMBL1046729 | 0.75 | PNMT (0.62) | PNMTTAAR1IDO1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4320106-A1 | ARYLACETYL INHIBITORS OF TG2 AND USES THEREOF | University Of Ottawa (CA) | 2024-02-14 | — | — | EP | disclosed |
| WO-2022213198-A1 | ARYLACETYL INHIBITORS OF TG2 AND USES THEREOF | UNIVERSITY OF OTTAWA (CA) | 2022-10-13 | — | — | WO | disclosed |
| EP-2900645-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | Bayer CropScience AG (DE) | 2015-08-05 | — | — | EP | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| CN-102532162-A | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2012-07-04 | — | — | CN | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-6562849-B1 | Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. | SANKYO COMPANY, LIMITED (JP) | 2003-05-13 | — | — | US | disclosed |
| US-20030078426-A1 | Amine derivative compounds | SANKYO COMPANY, LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1167366-A1 | AMINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
| US-4438277-A | Hydronaphthalene derivatives | SANKYO COMPANY, LIMITED (JP) | 1984-03-20 | — | — | US | disclosed |
| US-4361515-A | Antihyperlipemic dihydro-ML-236B derivatives, their preparation and use | SANKYO COMPANY, LIMITED (JP) | 1982-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | PNMT 4701/4885TAAR1 364/4885IDO1 3181/4885 |
| US-20030078426-A1 | Amine derivative compounds | H1-10, APOB, PRMT1 | PNMT 880/4885TAAR1 436/4885IDO1 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.